DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Key Terms
preeclampsiamedical
A pregnancy complication marked by high blood pressure and signs that organs like the liver or kidneys are under stress, often occurring after mid-pregnancy. Think of it as a car’s warning light during a long trip — it signals that the body’s systems are strained and require close monitoring or intervention. It matters to investors because the condition drives demand for diagnostics, treatments, clinical trials and regulatory decisions, which can affect healthcare company revenues and drug development risks.
fetal growth restrictionmedical
Fetal growth restriction (FGR) is a pregnancy condition in which the unborn baby does not reach the expected size or weight for its gestational age, often because of reduced nutrient or oxygen delivery from the placenta, maternal health problems, or fetal issues. Investors watch FGR because it drives demand for prenatal tests, monitoring tools, interventions and neonatal care, and can shape clinical trial needs, regulatory decisions and long‑term healthcare costs—think of it as a quality-control alert that a developing baby needs extra attention.
acute ischemic strokemedical
A sudden interruption of blood flow to a part of the brain that causes rapid loss of movement, speech, vision or other functions — like a blocked pipe cutting water to one room of a house. It matters to investors because its frequency, available treatments, medical devices and drug approvals drive health-care spending, influence the fortunes of biotech and device makers, and can quickly change revenue and regulatory risk profiles for companies in the sector.
MINNEAPOLIS--(BUSINESS WIRE)--
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that company management will participate in three upcoming investment bank conferences.
Details
TD Cowen 46th Annual Healthcare Conference
Boston, Massachusetts
Fireside chat with Rick Pauls, CEO, and Julie Krop, M.D., Chief Medical Officer, on Monday, March 2, 2026, at 11:50 a.m. Eastern Time (ET)
Barclays 28th Annual Global Healthcare Conference
Miami, Florida
Fireside chat with Rick Pauls, CEO on Wednesday, March 10, 2026, at 10:00 a.m. ET
Leerink Partners Global Healthcare Conference
Miami, Florida
Company presentation by Rick Pauls, CEO, on Wednesday, March 11, 2026, at 3:00 p.m. ET
If you are interested in arranging a 1×1 meeting with management, please contact your conference representative.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a current focus on preeclampsia, fetal growth restriction and acute ischemic stroke. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company’s website at www.diamedica.com.
